Investors Are Craving More from Cyclacel Pharmaceuticals Inc. [CYCC] Stocks: Here is Why

Over the past three months, Cyclacel Pharmaceuticals Inc. [CYCC] ended the trading day at $4.12 and exhibited a change of 9.87% with a 24 hour trading and reached upto the volume of 134.23K compared to its recorded trading volume of 0.6 million. CYCC generated a 1 year amount change with -59.61%. Though for Principal markets a year is counted as a long time period. By having a look at the most recent performance of this stock, in the last week its amount moved by 16.71% with an amount shift of 27.16% over the last month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 11, November 2020, Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results. According to news published on Yahoo Finance, – Conference Call Scheduled November 11, 2020 at 4:30 p.m. ET -.

Analyst Birdseye View:

The most recent analyst activity for Cyclacel Pharmaceuticals Inc. [NASDAQ:CYCC] stock was on September 07, 2018, when it was Initiated with a Buy rating from Ladenburg Thalmann. Before that, on April 27, 2020, ROTH Capital Recapitulated a Buy rating and elevated its amount target to $24. On October 16, 2015, H.C. Wainwright Initiated a Buy rating and boosted its price target on this stock to $5. On February 04, 2010, Roth Capital Initiated a Buy rating and increased its price target to $7. On October 28, 2009, Merriman Initiated a Buy rating. On August 12, 2008, Piper Jaffray Initiated a Buy rating and boosted its amount on this stock to $5. On March 12, 2008, Needham & Co Reiterated a Buy rating and decreased its target amount on this stock from $12 to $7. On March 12, 2008, Collins Stewart Reiterated a Buy rating and amplified its amount target to $13.

In the past 52 weeks of trading, this stock has oscillated between a low of $3.12 and a peak of $19.60. Right now, according to Wall Street analyst the average 12-month amount target is $21.33. At the most recent market close, shares of Cyclacel Pharmaceuticals Inc. [NASDAQ:CYCC] were valued at $4.12.


The Principal structure of this organization shows its whole liability to whole principal at 9.24 and the whole liability to whole assets at 7.78. It shows enduring liability to the whole principal at 9.24 and enduring liability to assets at 0.08 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.81 points at 1st support level, the second support level is making up to 3.50. But as of 1st resistance point, this stock is sitting at 4.31 and at 4.50 for 2nd resistance point.

Cyclacel Pharmaceuticals Inc. [CYCC] reported its earnings at -$0.47 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.55/share signifying the difference of 0.08 and 14.50% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.58 calling estimates for -$0.47/share with the difference of -0.11 depicting the surprise of -23.40%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Cyclacel Pharmaceuticals Inc. [NASDAQ:CYCC] is 15.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.91. Now if looking for a valuation of this stock’s amount to book ratio is 0.99.